Abstract: Compounds are provided to modulate the C5a receptor. The compounds have the following Formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
Type:
Grant
Filed:
October 23, 2019
Date of Patent:
February 22, 2022
Assignee:
ChemoCentryx, Inc.
Inventors:
Pingchen Fan, Antoni Krasinski, Venkat Reddy Mali, Shichang Miao, Sreenivas Punna, Yang Song, Valentino J. Stella, Yibin Zeng, Penglie Zhang
Abstract: Provided are in vitro and in vivo methods for determining whether a patient with Fabry disease will respond to treatment with a specific pharmacological chaperone.
Abstract: The present invention relates to a preservative-free ophthalmic composition for the reduction of elevated intraocular pressure containing Latanoprost or a combination of Latanoprost and Timolol and to a process for preparing such compositions.
Abstract: The disclosure relates to use of a triple formulation comprising a histone deacetylase, a cyclodextrin and polyethylene glycol or propylene glycol, and in the treatment and management of chronic pain.
Type:
Grant
Filed:
December 4, 2018
Date of Patent:
January 11, 2022
Assignees:
Northwestern University, The University of Notre Dame Du Lac
Inventors:
A. Vania Apkarian, Kasturi Haldar, Suhail Alam, Maria Virginia Centeno
Abstract: Mirtazapine is useful for the treatment and/or prophylaxis of medication overuse headache based on tension-type headache. Moreover, a pharmaceutical composition and/or the use of mirtazapine for the manufacture of a medicament, are useful against medication overuse headache based on tension-type headache, and the treatment of medication overuse headache based on tension-type headache.
Type:
Grant
Filed:
October 1, 2020
Date of Patent:
December 28, 2021
Assignees:
Curatis AG, Rigshospitalet—Glostrup, The University of Copenhagen
Inventors:
Arnim Pause, Lars Bendtsen, Rigmor Jensen, Jes Olesen
Abstract: The present invention concerns the use of emetine compounds for the treatment or prevention of Flavivirus infections, such as dengue virus infections. Aspects of the invention include methods for treating or preventing Flavivirus virus infection, such as dengue virus infection, by administering an emetine compound such as emetine or cephaeline, or a combination of two or more emetine compounds, to a subject in need thereof; methods for inhibiting Flavivirus infections such as dengue virus infections in a cell in vitro or in vivo; pharmaceutical compositions; packaged dosage formulations; and kits for treating or preventing Flavivirus infections, such dengue virus infections.
Type:
Grant
Filed:
December 18, 2019
Date of Patent:
December 28, 2021
Assignees:
Florida State University Research Foundation, Inc., The Johns Hopkins University, The United States of America, as Represented by the Secretary, Department of Health and Human Services
Inventors:
Hengli Tang, Emily M. Lee, Anil Mathew Tharappel, Hongjun Song, Guo-Li Ming, Wei Zheng, Miao Xu, Shu Yang, Ruili Huang, Wenwei Huang, Khalida Shamim, Hao Li
Abstract: Cannabidiol (CBD) is a cannabinoid designated chemically as 2-[(1R,6R)-3-Methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol. Its empirical formula is C21H30O2 and its molecular weight is 314.46. CBD is a cannabinoid that naturally occurs in the Cannabis sativa L. plant. CBD is a white to pale yellow crystalline solid which is insoluble in water and soluble in organic solvents. The present invention encompasses the surprising recognition that certain CBD preparations which are prepared from a botanical origin are more effective in treating diseases or disorders than preparations of CBD which are synthetic or purified to the extent no other impurities in the form of other cannabinoids are present. Prior CBD compositions have been prepared such that no psychoactive components, e.g., tetrahydrocannabinol (THC), remain in the final CBD preparation. Surprisingly, the absence of such minor impurities reduces the efficacy of CBD treatment.
Type:
Grant
Filed:
September 3, 2020
Date of Patent:
December 28, 2021
Assignee:
GW Research Limited
Inventors:
Geoffrey Guy, Volker Knappertz, Benjamin Whalley, Marie Woolley-Roberts, James Brodie, Katarzyna Lach-Falcone, Alan Sutton, Royston Gray, Rohini Rajyalaxmi Rana
Abstract: This disclosure is directed to treatment of addictions and primary impulse-control disorders using phosphodiesterase 7 (PDE7) inhibitors, alone or in combination with other therapeutic agents.
Type:
Grant
Filed:
January 15, 2018
Date of Patent:
December 28, 2021
Assignee:
OMEROS CORPORATION
Inventors:
Gregory A. Demopulos, George A. Gaitanaris
Abstract: The invention discloses methods for screening out of a BRaf inhibitor population, suitable BRaf inhibitors as candidates for clinical development of drugs for treating and/or preventing cutaneous reaction caused by treatment with EGFR inhibitor and/or PI3K inhibitors.
Abstract: Provided is a free-polyunsaturated-fatty-acid-containing composition that has a total metal content of 0.1 ppm or less and that comprises at least one free polyunsaturated fatty acid having 20 or more carbon atoms, in an amount that is at least 80.0% of the amount of fatty acids in the composition; and a method for manufacturing a free-polyunsaturated-fatty-acid-containing composition, comprising: providing a raw material composition containing at least one polyunsaturated fatty acid having 20 or more carbon atoms; performing a hydrolysis treatment on a reaction solution prepared by combining the provided raw material composition, a lower alcohol, water having a total metal content of 0.01 ppm or less, and an alkali catalyst; and limiting the contact between the reaction composition and the metal after the hydrolysis treatment so that the product T [cm2×days] of the contact surface area [cm2] per 1 g and the contact time [days] between the composition and the metal is 100 or less.
Abstract: The present application relates to a method of treating an inflammatory skin condition by administering a pharmaceutical composition comprising a reduced dose of minocycline to a subject in need thereof, wherein said administration provides an effective plasma or interstitial fluid concentration of minocycline for treating the inflammatory skin condition.
Abstract: The invention disclosed herein relates to synergistic nutritional compositions for enhancing cellular ATP efficiency. Particularly, the invention relates to a synergistic, efficient, nutritional composition for promoting cellular ATP production comprising a therapeutically active exogenous combination of a stabilized oxaloacetate and a biotin-manganese complex along with pharmaceutically acceptable excipients; wherein the stabilized oxaloacetate and the biotin-manganese or salts thereof are present in a weight ratio ranging from 1:0.01 to 1:0.2. Further, the present synergistic nutritional composition is useful for treating ATP deficiency disorders, age-related metabolic disorders, neurodegenerative diseases, cardiovascular diseases, bone related disorders, central nervous system diseases, cognitive disorders and like thereof.
Abstract: Disclosed are compositions, methods of treatment using the compositions and methods of preparing the compositions for the treatment of acne vulgaris. The compositions include succinic acid, Brij®-30 and a molecular penetration enhancer in a pharmaceutically acceptable preparation. The molecular penetration enhancer may include one or more of DMSO, dimethyl isosorbide, lauryl lactate and isopropyl myristate.
Type:
Grant
Filed:
May 25, 2017
Date of Patent:
October 26, 2021
Assignee:
Dermala Inc.
Inventors:
Lada Rasochova, Edward T Kisak, John Newsam
Abstract: The present invention provides pharmaceutical composition of antineoplastic alkylating agent in oral suspension dosage form. The oral suspension composition comprises of alkylating agent with other pharmaceutical excipients such as vehicle, preservative, antioxidant, suspending agent, surfactant, sweetener and flavouring agent. The present invention is an oral suspension having improved stability and palatability. The present invention also provides oral solution with flavor that has masked bitter taste of the drug. Further, the present invention also provides a process for preparation thereof.
Abstract: The present invention relates to enhanced omega-3 formulations, and in particular to formulations comprising a phospholipid fraction and a triglyceride fraction in combinations with agents that provide a formulation with improved viscosity and dispersion characteristics.
Abstract: The invention provides for novel MAP kinase inhibitors and compositions comprising the same. In some embodiments, the MAP kinase inhibitors are p38? MAP kinase inhibitors. The invention further provides for methods for treatment of diseases comprising administration of MAP kinase inhibitors or compositions comprising MAP kinase inhibitors. In some embodiments, the disease is Alzheimer's Disease, ALS, Huntington's Disease or Parkinson's Disease.
Type:
Grant
Filed:
August 27, 2019
Date of Patent:
October 19, 2021
Assignees:
The Trustees of Columbia University in the City of New York, Northwestern University
Inventors:
Ottavio Arancio, Daniel Martin Watterson, Jeffrey Claude Pelletier, Saktimayee Mitra Roy
Abstract: Compositions including small molecule mitofusin activators are described. The mitofusin activators are useful for treating diseases or disorders associated with a mitochondria-associated disease, disorder, or condition such as diseases or disorders associated with mitofusin 1 (MFN1) and/or mitofusin 2 (MFN2), or mitochondrial dysfunction. Methods of treatment, pharmaceutical formulations, and screening methods for identifying compounds that activate mitochondrial fusion are also described.
Abstract: The present invention relates to a pharmaceutical composition containing a monoacetyldiacyiglycerol compound as an active ingredient for preventing or treating asthma, and a functional health food composition for preventing or treating asthma. The monoacetyldiacylglycerol compound of the present invention inhibits the expression of IL-4 in EL-4 cells, which are mouse T cell lymphoma cells, reduces hypersensitivity of airway in an asthma-induced animal model, and inhibits the infiltration of inflammatory cells into the bronchial tube. In addition, the compounds of the present invention inhibit the generation of IgE in the serum and bronchoalveolar lavage fluid, have an excellent effect of inhibiting the expression of Th2 cytokines (IL-4, IL-5, and IL-13) in the lung, thereby overcome side effects of the currently used therapeutic agents for asthma, have no toxicity, and exhibit a superior therapeutic effect, and thus can be useful as a composition for preventing, treating, and alleviating asthma.
Type:
Grant
Filed:
September 11, 2018
Date of Patent:
October 5, 2021
Assignee:
Enzychem Lifesciences Corporation
Inventors:
Sei-Ryang Oh, Kyung Seop Ahn, Su Ui Lee, In Sik Shin, Na-Rae Shin, Tae-Suk Lee, JongKoo Kang, Young-Sik Jung, Yong-Hae Han, Ki Young Sohn
Abstract: Disclosed herein are “ketonnabidiol” or “ketannabidiol” compositions including a combination of: (1) cannabidiol (CBD) and/or cannabidiolic acid (CBDA); (2) a ketone body component such as beta-hydroxybutyrate (BHB) and/or acetoacetate; and (3) a dietetically or pharmaceutically acceptable carrier. Also disclosed herein are methods of using such ketonnabidiol compositions for producing desired physiological effects, such as fat loss, in a mammal. The ketonnabidiol compositions beneficially enhance fat loss through ketosis while also reducing the duration and/or severity of unpleasant “keto flu” symptoms typically associated with ketosis.